A new leadless pacemaker with atrioventricular synchronous pacing replacing a still working VVI leadless pacemaker: a case report.
Atrioventricular block
Atrioventricular synchronous pacing
Case report
Leadless pacemaker
Micra TPS
Pacemaker syndrome
Journal
European heart journal. Case reports
ISSN: 2514-2119
Titre abrégé: Eur Heart J Case Rep
Pays: England
ID NLM: 101730741
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
21
03
2021
revised:
18
04
2021
accepted:
13
07
2021
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
20
8
2021
Statut:
epublish
Résumé
A new intracardiac leadless pacemaker (ILP) has been developed to ensure atrioventricular (AV) synchrony (AVS) during ventricular pacing (VP). Recent studies have shown the feasibility and safety of accelerometer-based atrial sensing and an improvement in AVS among patients with atrioventricular block implanted with the Micra AV ILP (Medtronic Inc., Minneapolis, MN, USA). However, no data exists about the benefits of a VDD ILP in patients wearing a still working VVI Nanostim ILP (St Jude Medical, St Paul, MN, USA). We describe the feasibility of the procedure and the absence of device-related adverse events in the short-term follow-up. We present the case of a 72-year-old man implanted with a VVI ILP (Nanostim, St Jude Medical, St Paul, MN, USA) on May 2014, who has developed symptomatic high percentage of VVI asynchronous pacing and was treated with an upgrade to synchronous AV pacemaker (PM) ILP-Micra AV (Medtronic Inc., Minneapolis, MN, USA), which has improved symptoms and functional class. Intracardiac leadless pacemakers represent the best current option for patients requiring PM implantation who are at high risk of infection and bleeding. Our case shows that the new AVS ILP is a good alternative to VVI ILP in patients with sinus rhythm and a strong need for VP.
Sections du résumé
BACKGROUND
BACKGROUND
A new intracardiac leadless pacemaker (ILP) has been developed to ensure atrioventricular (AV) synchrony (AVS) during ventricular pacing (VP). Recent studies have shown the feasibility and safety of accelerometer-based atrial sensing and an improvement in AVS among patients with atrioventricular block implanted with the Micra AV ILP (Medtronic Inc., Minneapolis, MN, USA). However, no data exists about the benefits of a VDD ILP in patients wearing a still working VVI Nanostim ILP (St Jude Medical, St Paul, MN, USA). We describe the feasibility of the procedure and the absence of device-related adverse events in the short-term follow-up.
CASE SUMMARY
METHODS
We present the case of a 72-year-old man implanted with a VVI ILP (Nanostim, St Jude Medical, St Paul, MN, USA) on May 2014, who has developed symptomatic high percentage of VVI asynchronous pacing and was treated with an upgrade to synchronous AV pacemaker (PM) ILP-Micra AV (Medtronic Inc., Minneapolis, MN, USA), which has improved symptoms and functional class.
DISCUSSION
CONCLUSIONS
Intracardiac leadless pacemakers represent the best current option for patients requiring PM implantation who are at high risk of infection and bleeding. Our case shows that the new AVS ILP is a good alternative to VVI ILP in patients with sinus rhythm and a strong need for VP.
Identifiants
pubmed: 34409251
doi: 10.1093/ehjcr/ytab305
pii: ytab305
pmc: PMC8364773
doi:
Types de publication
Case Reports
Langues
eng
Pagination
ytab305Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
JACC Clin Electrophysiol. 2020 Jan;6(1):94-106
pubmed: 31709982
Europace. 2013 Aug;15(8):1070-118
pubmed: 23801827
Eur Heart J. 2015 Oct 1;36(37):2510-9
pubmed: 26045305
Pacing Clin Electrophysiol. 2010 May;33(5):583-9
pubmed: 20015129
Heart Rhythm. 2018 Sep;15(9):1363-1371
pubmed: 29758405
Jpn Circ J. 1986 Sep;50(9):799-807
pubmed: 3795453
Europace. 2018 Sep 1;20(9):1491-1497
pubmed: 29365073
N Engl J Med. 2016 Feb 11;374(6):533-41
pubmed: 26551877
J Interv Card Electrophysiol. 2018 Mar;51(2):161-162
pubmed: 29335839
Europace. 2018 Feb 1;20(2):391
pubmed: 29016787